[EN] PHARMACEUTICAL COMPOSITION COMPRISING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE<br/>[FR] COMPOSITION PHARMACEUTIQUE COMPRENANT DE LA 5-MÉTHOXY-N, N-DIMÉTHYLTRYPTAMINE
申请人:BECKLEY PSYTECH LTD
公开号:WO2021250435A1
公开(公告)日:2021-12-16
An intranasal composition comprising a dosage amount of 50-150mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.
一种鼻内制剂,包括50-150mg/ml 5-甲氧基-N,N-二甲基色胺(5MeODMT)的剂量量和液体介质,其中5MeODMT以5MeODMT的氯化物盐(5MeODMT盐酸盐)的形式配制,5MeODMT盐酸盐是结晶的,并具有以下特征之一或多个:XRPD衍射图中的峰值;DSC热图中的吸热事件;TGA热图中的分解起始点;以及DVS等温线剖面。